


# Anti-Mullerian Hormone (AMH) Analogue

**THERAPEUTIC: Women's health**

Product Type	Therapeutic protein (engineered)
Indication/ROA	Oncofertility, epithelial ovarian cancer, reversible contraceptive, protection of ovarian reserve
Target/MoA	Highly potent AMH analogue with enhanced affinity for AMH Type 2 Receptor. AMH is a key regulator of reproductive organ differentiation and ovarian follicular development.
Development Stage	Lead series
Brief Description & Differentiation	<p>Anti-Müllerian Hormone (AMH) is a key regulator of reproductive organ differentiation and ovarian follicular development. AMH is the best available measure of 'ovarian reserve', that is the quantity and quality of primordial follicles. In the absence of AMH, primordial follicles are recruited at a faster rate, resulting in a depleted ovarian reserve at a younger age. Furthermore, it has been demonstrated that AMH could inhibit the growth of epithelial ovarian cancer.</p> <p>We have developed potent AHM analogues with potential applications in:</p> <ul style="list-style-type: none"> <li>• Oncofertility (i.e. preservation of fertility during and after cancer treatments)</li> <li>• Treatment of certain gynaecologic tumours</li> <li>• Reversible contraceptive agent</li> </ul>
Research Team	A/Prof. Craig Harrison, Dr. Kelly Walton
Intellectual Property	Novel compositions. Patent to be filed.
Key Publications	Confidential
Future	Further optimisation and demonstration of POC in preclinical disease models. Progress to manufacturing scale up and formal preclinical studies enabling human testing in phase 1a/b clinical trial.

## ➤ Key Data

We have generated highly potent AHM analogues and are currently generating additional proof of principle functional data.



**Figure 1. Potency of AMH analogues.** Activity read out for AMH analogues in a granulosa cell luciferase